Unlocking efficiency in drug discovery: GE Healthcare’s The Pulse visits Sygnature Discovery
The Pulse recently interviewed Dr Scott Pollack, Associate Director, Biophysics and Enzymology, and Dr Paul Clewlow, Senior VP, Business Development, about how Sygnature Discovery is accelerating their ambitious clients’ drug discovery programs and helping them to increase their productivity through the application of cutting-edge technology, such as the Biacore 8K surface plasmon resonance equipment that was recently added to Sygnature’s Bioscience Department.
To read The Pulse article, go to: http://newsroom.gehealthcare.com/unlocking-efficiency-in-drug-discovery/
